x

Nextgen

Regeneron Announces Clinical Trial of First U.S. COVID Antibody Cocktail

NEW YORK – Regeneron Pharmaceuticals announced in a press release on June 11 that the first U.S. clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19, began on June 10. Greek-American George D. Yancopoulos, MD, PhD, Co-Founder, President and Chief Scientific Officer of Regeneron, had told The National Herald in an interview in March about the effort to develop the antibody cocktail, noting then that trials could begin as early as June.

According to the press release, the REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure (such as healthcare workers or first responders) and uninfected people with close exposure to a COVID-19 patient (such as the patient's housemate). The placebo-controlled trials will be conducted at multiple sites.

“We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral 'escape,' a critical precaution in the midst of an ongoing global pandemic,” said Dr. Yancopoulos said in the press release. “REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick – and could be available much sooner than a vaccine. The antibody cocktail approach may also have long-term utility for elderly and immuno-compromised patients, who often do not respond well to vaccines. Ultimately, the world needs multiple solutions for COVID-19, and the innovative biopharma industry is collectively working hard to help as many people as possible with a variety of complementary approaches.”

Regeneron used the same “rapid response” capabilities and cocktail approach to develop REGN-EB3, a novel triple antibody treatment for Ebola that is now under regulatory review by the U.S. Food and Drug Administration (FDA). REGN-COV2's preclinical development and preclinical/clinical manufacturing has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

The first two adaptive Phase 1/2/3 studies are evaluating REGN-COV2 (REGN10933+REGN10987) as a treatment for hospitalized and non-hospitalized patients with COVID-19. The Phase 1 portion will focus on virologic and safety endpoints, and the Phase 2 portion will focus on virologic and clinical endpoints. Data from the Phase 1 and Phase 2 studies will be used to refine the endpoints and determine size for the Phase 3 studies.

"We are particularly excited to begin studies of REGN-COV2, which is a novel antibody cocktail targeted specifically against SARS-CoV-2," said trial investigator Dr. Suraj Saggar, Chief of Infectious Disease at Holy Name Medical Center in Teaneck, NJ. "Over the last long months, we have learned that repurposing existing medicines unfortunately does not offer a broadly effective solution for COVID-19. For this reason, we need to investigate custom-designed approaches like REGN-COV2. The first studies will evaluate if REGN-COV2 can improve disease outcomes in both hospitalized and non-hospitalized patients with COVID-19."

About Regeneron's Anti-Viral Antibodies

When faced with a harmful pathogen, such as a virus or bacteria, the human immune system typically produces antibodies to fight the invader. Specifically, the immune system produces “anti-viral” antibodies that recognize, bind, and kill or neutralize the virus. Vaccination involves injecting a dead or weakened virus, or a critical small piece of a virus, to induce this protective immune response, resulting in the same antibodies the immune system would typically make in a person who actually had the infectious disease.

Regeneron's core technologies allow for rapid and efficient generation of these protective anti-viral antibodies outside of the body, derived from either genetically-humanized mice or convalescent humans. The resulting antibodies correspond to the most potent of anti-viral antibodies that could be elicited by a vaccine or through exposure to a pathogen. These antibodies can be delivered to people via injection, providing "passive immunity" and protection from the disease immediately, though they must be re-administered to remain effective over time. These antibodies can also treat an existing infection, unlike vaccines which can only be used preventatively.

The concept that drug cocktails can prevent viral escape has previously been demonstrated for traditional antiviral drugs used to treat HIV and other viruses. In the upcoming Science publications, Regeneron scientists report the fundamental realization that this can also be true for antibody-based therapies. Regeneron's preclinical studies demonstrate that, in the setting of a single therapeutic antibody that blocks the ability of a virus to infect healthy cells, spontaneously arising mutant forms of the virus are able to “escape” or evade the antibody's blocking action. These mutants are then “selected” (i.e., are able to survive and proliferate despite the single antibody treatment) and may ultimately become the dominant strain of the virus. Regeneron therefore pursues a multi-antibody cocktail approach designed to decrease the potential for the virus to escape.

Regeneron has developed additional technologies that allow for the large-scale manufacturing and purification of these anti-viral antibodies, potentially allowing many people to be granted immunity before vaccines become widely available.

More information about Regeneron is available online: regeneron.com.

RELATED

Welcome to TNH’s Takeover! In collaboration with The Hellenic Initiative (THI), The National Herald and THI have begun a partnership to introduce the NEXTGEN of Greek/Cypriot ‘movers and shakers’ to the rest of our Diaspora community around the world.

Top Stories

Culture

If you are reading this today, you can thank your parents, grandparents, great-grandparents, and previous ancestors for your existence.

Politics

A former senator, minister, cabinet secretary, chief of staff to Australian former PM John Howard for more than a decade, Arthur Synodinos is Australia’s ambassador to the United States since 2020.

General News

Anton "Tony" Mandros, 87, of Portsmouth, RI, passed to his eternal reward on January 19.

Video

In Mourning Yet Again, NYC Prepares to Honor Fallen Officer

NEW YORK — A city reeling from a recent spate of violence prepared to lay to rest a rookie police officer being hailed as an inspiration to his immigrant community, as investigators sought to make sense of a domestic dispute that left another officer "fighting for his life.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.